Abstract Using population-based surveillance from 2020 to 2024, we examined recurrence through 180 days among adults with initial community-associated Clostridioides difficile infection (CDI). Fidaxomicin was associated with a 50% lower risk of recurrence compared with vancomycin. These findings are consistent with current guideline recommendations and are relevant to outpatient management of initial CDI.
Hawco et al. (Thu,) studied this question.